What it is
AOD-9604 is a synthetic copy of a short stretch of human growth hormone — the region usually written as residues 176 to 191, near the end of the molecule — with an extra tyrosine attached. It is a fragment, not a hormone, and it is sold under both names: AOD-9604 and HGH fragment 176-191 are treated as the same product in the market, though strictly the added tyrosine distinguishes them.
The idea behind it is specific and testable. Growth hormone does several things at once, and two of them are usually wanted separately: it makes tissues grow, and it changes how the body handles fat. The proposal was that this fragment carries the second effect without the first — a fat-loss agent with none of growth hormone's other consequences.
That is a good hypothesis. What follows is what happened to it.
The file, counted
| Measure | AOD-9604 |
|---|---|
| PubMed title/abstract records | 22 |
| Of those, tagged for humans | 18 |
| Randomized controlled trials | 0 |
| Interventional registrations | 0 |
| US drug-label records | 0 |
| Papers about detecting it in urine | 7 |
| Primary human studies of what it does | 0 |
Twenty-two records is small enough to read in full, so that is what we did. They sort cleanly.
The largest group is drug testing
Seven of the twenty-two are anti-doping analytical chemistry, in serious journals: urine screening methods for peptides under 2 kDa, laboratory studies of how the compound breaks down, mass-spectrometry reviews of sports drug testing, and the characterisation of pharmaceutical preparations seized by national authorities.
One of them explains the rest. A 2013 paper found that AOD-9604 does not affect the standard WADA growth-hormone isoform immunoassay — the routine test for growth hormone does not see it. That is precisely the property that made a dedicated detection method necessary, and a compound earns that kind of attention by circulating widely, not by being studied.
So the largest coherent body of knowledge about this compound is how to find it in a urine sample. There are more papers on that than there are primary human studies of what it does, because the second number is zero.
The original work is rodent work, and it is old
- A metabolic study of the synthetic lipolytic domain, in Hormone Research, 2000.
- Two studies of chronic treatment in obese mice, in Endocrinology and the International Journal of Obesity, 2001.
- A study injecting it into rabbit joints for osteoarthritis, 2015 — pointing at a different use entirely.
The central claim — fat metabolism separated from growth — was examined in mice around twenty-five years ago and has not been tested in the published human literature since.
The human trials that are cited but not published
Human obesity studies are routinely attributed to the compound's original developer, and it is entirely plausible they were conducted. They are not findable as results publications. What the index holds is three entries in a compilation series called Gateways to Clinical Trials, published in 2003, 2003 and 2005 — a series that lists trials under way rather than reporting their outcomes.
The distinction matters for anyone weighing a claim. A results publication states what was given, to how many people, for how long, and what happened. A compilation entry states that a study exists. No figure or outcome claim we examined for this compound traces back to the former, and several are presented as though they did.
What this pattern means
This library keeps finding different reasons a compound's evidence looks thinner than its marketing. AOD-9604 adds one that is unusual: a research file whose centre of gravity is forensic rather than clinical.
That is not a neutral observation. A compound accumulates detection literature because laboratories need to catch it, and laboratories need to catch it because people are using it — which tells you about circulation, not about effect. Our MOTS-c entry documents a registry that turned out not to withstand checking, and our VIP entry documents a huge literature that measures rather than administers. Here the literature is real, competent and mostly about the wrong question.
What is actually sold
Lyophilised powder for reconstitution, sold as AOD-9604 or HGH fragment 176-191, marketed almost entirely for fat loss; occasionally compounded or topical preparations.
It is usually priced beside the fat-vessel-targeting construct sold as adipotide, which is a different kind of thing altogether — designed to destroy the blood supply of fat tissue rather than to signal to it, and carrying a single human trial that stopped with four participants.
There is no approved product anywhere, no trial registration and no published human results to support the marketing. The hypothesis behind the compound is a reasonable one and remains, in humans, untested. Our entry on how to read this library sets out the difference between a compound being real and a product being established.